NIHR Newcastle Biomedical Research Centre (BRC)

What NIHR Newcastle Biomedical Research Centre (BRC) does

The NIHR Newcastle Biomedical Research Centre (BRC) is a publicly funded translational research centre operating under the UK's National Institute for Health and Care Research (NIHR). It is hosted by The Newcastle upon Tyne Hospitals NHS Foundation Trust in partnership with Newcastle University and the Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust, and is the only BRC located in the North East of England. The organisation is structured around eight dedicated research themes focused on ageing and multiple long-term conditions: Ageing/Sarcopenia/Multimorbidity; Dementia/Mental Health/Neurodegeneration; Digital Health/Ageing Innovation/Inclusion; Informatics/Precision Care; Liver Disease/Multimorbidity/Lifestyle; Musculoskeletal Disease/Inflammation Medicine; Neuromuscular Disease/Rare Diseases/Mitochondrial Dysfunction; and Skin Disease/Oral Disease/Immunogenomics.

The BRC's technical capabilities include whole genome sequencing for rare disease diagnosis (with demonstrated 25% new diagnosis rate), MRI/MRS imaging, muscle imaging, adaptive optics for retinal imaging, fine needle aspiration of lymph nodes combined with ultrasound, and cellular electrodiagnostics. It also developed and maintains the Plan4PPIE.com digital planning tool. Specific research assets include the 100,000 Genomes Project dataset, the AuToDeCRA tolerogenic dendritic cell therapy programme, the TRAC Study in CYLD cutaneous syndrome, the MASS Lifecourse Study, and the North Star Assessment for Limb Girdle Muscular Dystrophies (incorporated in 7 clinical trial protocols). Active partnerships span Boehringer Ingelheim, the Jain Foundation, UKRI, the LifeArc Centre for Rare Disease Trials, TREAT-NMD, Mobilise-D, NIHR Dementia TRC, and the Multiple Long-Term Conditions Cross-NIHR Collaboration.

The BRC does not operate a commercial revenue model. It is funded through NIHR government grants, industry-sponsored research agreements, and contributions from its host institutions. Research outputs are delivered into clinical practice through its NHS partner trusts, and findings are disseminated via international research consortia. In 2024 the centre engaged approximately 3,600 research participants across 315 active projects, supported by 74 research staff and 31 PhD students.

Name

NIHR Newcastle Biomedical Research Centre (BRC)

Legal name

NIHR Newcastle Biomedical Research Centre (BRC)

Website

https://newcastlebrc.nihr.ac.uk

Company type

Public

Operating status

Operating

Headcount range

1–10 employees

Short description

The NIHR Newcastle Biomedical Research Centre is a publicly funded translational research centre under the UK's NIHR, operating eight research themes on ageing and multiple long-term conditions, hosted by NHS Foundation Trusts in partnership with Newcastle University.

Ownership category

akta.pro rank

Product category

Translational Biomedical Research

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Genomics & Next-Generation Sequencing (NGS) Services (HLAGANAA)

akta.pro secondary industries

Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Genomic Profiling & Sequencing-Based Precision Medicine (HLAAANAA), Molecular Diagnostics & Genomics Laboratories (HLAFAMAE), Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ), Neurogenetics & Rare Neurologic Diseases (HLAKAIAO)

Keywords

• Translational biomedical research
• Clinical research services
• Ageing and multimorbidity
• Rare disease diagnostics
• Patient public involvement

Headquarters

HQ city

Newcastle upon Tyne

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Others

Revenue model

1. NIHR Government Funding: As part of the National Institute for Health and Care Research (NIHR), the BRC receives government funding to support translational and clinical research infrastructure. The BRC is hosted by The Newcastle upon Tyne Hospitals NHS Foundation Trust in partnership with Newcastle University and Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

The NIHR Newcastle BRC conducts translational clinical research focused on ageing and multiple long-term conditions, organised across eight research themes covering ageing research, multiple long-term conditions, neuroinflammation and neurodegeneration, neuromuscular and skeletal disease, rare disease diagnostics, metabolomics and systems biomedicine, oral and systemic disease, and patient and public involvement. It supports laboratory-to-clinic translation using advanced imaging, genomics, mass spectrometry and big-data capabilities hosted jointly by Newcastle upon Tyne Hospitals NHS Foundation Trust, CNTW NHS Foundation Trust and Newcastle University.

Product overview

The NIHR Newcastle Biomedical Research Centre (BRC) is a research center focused on translating scientific discoveries into treatments, diagnostics, and health technologies for patients. Rather than a traditional product company, it operates as a research consortium offering eight distinct research themes covering ageing, dementia, digital health, informatics, liver disease, musculoskeletal conditions, neuromuscular/rare diseases, and skin disease/immunogenomics. The BRC also provides supporting services including training and professional development programmes, patient and public involvement and engagement activities, and the Plan4PPIE.com digital planning tool for PPIE activities.

Differentiator

Problem solved

Functional benefit

Brands

• 100,000 Genomes Project: World-first whole genome sequencing study for rare disease diagnosis involving 4,660 people from 2,183 families
• PAuSing-Post-COVID Fatigue
• ADVANCE Study
• Lymph Node Research UK
• AuToDeCRA

Products and services

• Ageing, Sarcopenia and Multimorbidity Research Translational research programme studying the biology of ageing, sarcopenia, frailty and multiple long-term conditions, designed for NHS patients, clinical teams and academic collaborators seeking evidence-based interventions.

Quantifiable outcome

• Whole genome sequencing led to new diagnosis for 25% of rare disease participants, with 14% found in regions missed by conventional methods
• +2 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

16 partnerships are on record, tiered core, major and minor.

• Lymph Node Research UKcoreStrategic or Co-development Partner · 17 June 2026A £1.7 million UK-wide research network dedicated to unlocking the role of lymph nodes in infection, immunity and inflammatory disease. Led by University of Oxford, Cardiff University, and Newcastle University (with BRC's Prof John Isaacs as Principal Investigator at Newcastle). Established a national network of 10 specialist lymph node research centres. Positions UK as a global leader in human lymph node research with applications in vaccine development, autoimmune diseases such as rheumatoid arthritis, and cancer research. BRC's involvement includes trials of AuToDeCRA for rheumatoid arthritis.
• Boehringer IngelheimcoreStrategic or Co-development Partner · 12 January 2024Pharmaceutical partner funding the £30M ADVANCE (Accelerating Discovery: Actionable NASH Cirrhosis Endpoints) study led by Newcastle University researchers (Prof Quentin Anstee) and University of Edinburgh. Study is the most detailed observational study of NASH cirrhosis enrolling the largest number of patients, aiming to identify translational biomarkers and accelerate development of future therapies for liver cirrhosis. Reflects Boehringer Ingelheim's commitment to cardiovascular, renal and metabolic diseases.
• The Newcastle upon Tyne Hospitals NHS Foundation TrustcoreStrategic or Co-development PartnerHost institution for the NIHR Newcastle BRC. Provides NHS clinical infrastructure and patient access for translational research across all 8 BRC themes.
• Newcastle UniversitycoreStrategic or Co-development PartnerAcademic partner and co-host of the NIHR Newcastle BRC. Provides research infrastructure, academic staff, and translational research expertise across all BRC themes.
• Cumbria, Northumberland, Tyne and Wear NHS Foundation TrustcoreStrategic or Co-development PartnerPartner NHS Trust hosting the NIHR Newcastle BRC, providing clinical research infrastructure particularly for mental health and community care settings.
• NIHR Dementia Translational Research CollaborationcoreStrategic or Co-development PartnerNIHR Dementia Translational Research Collaboration — Trials Network (D-TRC-TN) backed by £49.9m government funding. Newcastle BRC researchers (Prof John-Paul Taylor as Deputy Chair) contribute to expanding early phase dementia trials across the UK, developing trial sites and widening access to diverse populations.
• Mobilise-D ConsortiumcoreStrategic or Co-development PartnerEU IMIJ2 funded consortium coordinated by Prof Lynn Rochester (BRC Digital Health Theme Co-Lead) to develop and validate real-world digital mobility biomarkers for neurodegenerative disease and ageing research.
• NIHR Clinical Research Network (CRN)majorStrategic or Co-development PartnerBRC Theme Co-Lead Prof Lynn Rochester previously led NIHR CRN Speciality Cluster E with strategic oversight of the NIHR research portfolio in ageing, dementia, neurodegeneration, neurological disorders and genetics.
• TREAT-NMDcoreStrategic or Co-development PartnerEU FP6 funded network of excellence for genetic neuromuscular diseases co-founded by Prof Volker Straub. TREAT-NMD Services Ltd. spun out from Newcastle University. Network coordinates global translational research in neuromuscular diseases.
• MJ Fox Foundation Endpoints Advisory BoardminorStrategic or Co-development PartnerProf Lynn Rochester serves on the MJ Fox Foundation Endpoints Advisory Board, contributing to Parkinson's disease research endpoint standardisation.
• Multiple Long-Term Conditions Cross NIHR Collaboration (MLTC CNC)coreStrategic or Co-development PartnerEstablished December 2022, hosted by Newcastle University in partnership with University of Leicester. Innovative initiative bringing together NIHR translational, applied and policy research infrastructure to identify common research priorities and maximise impact in MLTC research. Co-chaired by Prof Avan Aihie Sayer.
• LifeArc Centre for Acceleration of Rare Disease Trials (ARDT)majorStrategic or Co-development PartnerLifeArc centre aimed at accelerating clinical trials and improving access to new therapies for people living with rare disease. Prof Neil Rajan is part of this centre, exemplifying translational research in rare genetic skin disease.
• British Association of Dermatologists (BAD) Skin Genetics GroupmajorStrategic or Co-development PartnerProf Neil Rajan chairs the BAD Skin Genetics Group, advancing genomic literacy, supporting national registries, shaping policy, and developing educational resources for healthcare professionals.
• Patient Organisations (Lynch Syndrome UK, Ichthyosis Support Group, DEBRA UK, PC Project)majorStrategic or Co-development PartnerProf Neil Rajan works with patient groups including Lynch Syndrome UK, Ichthyosis Support Group, DEBRA UK, and PC Project to amplify the patient voice in research priority setting and jointly advance understanding of cancer predisposition using skin tumours.
• UK Biobank Dementia Working GroupminorStrategic or Co-development PartnerProf Lynn Rochester serves on the UK Biobank Dementia working group, contributing to large-scale population data research in dementia.
• International Parkinson's Disease and Movement Disorders Society Task Force on TechnologyminorStrategic or Co-development PartnerProf Lynn Rochester serves on this international task force focused on technology standards in movement disorder research.

Scale indicators10 records

Recent moves6 records

Expansion highlights7 records

Direct peers

• NIHR Cambridge Biomedical Research Centre: Sister NIHR BRC hosted by Cambridge University Hospitals and the University of Cambridge, sharing the same government funding model, NHS partnership structure, and translational research mandate. Stronger genomics and oncology orientation than Newcastle.
• NIHR Imperial Biomedical Research Centre: NIHR BRC at Imperial College London and Imperial College Healthcare NHS Trust. Operates an identical translational research infrastructure with comparable thematic scope, providing a benchmark for London-based urban BRCs versus Newcastle's regional model.
• NIHR University College London Hospitals Biomedical Research Centre: NIHR BRC at UCL and UCLH, one of the largest UK BRCs by funding allocation. Operates under the same NIHR framework with strong overlap in experimental medicine and translational research.
• NIHR Manchester Biomedical Research Centre: NIHR BRC hosted by Manchester University NHS Foundation Trust and the University of Manchester. Closely comparable in regional/Northern England positioning, with thematic overlap in ageing, dementia, and rare diseases.
• NIHR Oxford Biomedical Research Centre: Another NIHR-designated Biomedical Research Centre hosted by Oxford University Hospitals and the University of Oxford. Directly comparable structure, funding model, and translational research mission, though Oxford's thematic focus differs (e.g., heavier emphasis on cancer, cardiovascular, and surgical innovation).

Others

• John Walton Muscular Dystrophy Research Centre: Newcastle University-hosted centre directed by Prof Volker Straub, effectively embedded within the BRC's neuromuscular theme. Highly adjacent in rare disease neuromuscular research but operates as a specialised disease-focused centre rather than a multi-theme translational hub.

Regional players

• Mayo Clinic: US-based academic medical centre with comparable translational research infrastructure, multi-specialty clinical delivery, and NIH-equivalent funding flows. Comparable thematically across ageing, rare disease, and biomarker discovery, but operates under US reimbursement and funding models rather than the UK NIHR framework.

Broad incumbents

• Wellcome Sanger Institute: UK-based genomics and bioinformatics research institute with significantly larger scale and broader genomic research portfolio than Newcastle BRC. Comparable in genomic sequencing capability but operates as a standalone genomics powerhouse rather than a multi-theme clinical translational centre.
• Francis Crick Institute: Large UK biomedical discovery research institute with substantially greater scale and broader biomedical scope. Comparable as a flagship UK translational/biomedical research entity but operates without the NHS clinical delivery arm that defines the BRC model.

Emerging players

• Edinburgh Medical School (Centre for Inflammation Research): Co-lead institution on the £30M ADVANCE NASH cirrhosis study with Newcastle. Comparable in liver disease and inflammation research but lacks the consolidated multi-theme BRC structure.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/Muzz_Haniffa
• LinkedInlinkedin.com/company/nihr-newcastle-brc

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NIHR Newcastle Biomedical Research Centre (BRC)